NovaBridge Biosciences (NBP) Equity Average (2018 - 2025)

NovaBridge Biosciences (NBP) has 7 years of Equity Average data on file, last reported at $244.9 million in Q4 2025.

• Quarterly Equity Average rose 16.9% year-over-year to $244.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $244.9 million (up 16.9% YoY) and the FY2025 annual result came in at $216.1 million, down 2.62% from the prior year.
• Equity Average advanced to $244.9 million in Q4 2025 per NBP's latest filing, from $227.8 million in the prior quarter.
• Across five years, Equity Average topped out at $847.3 million in Q2 2021 and bottomed at $197.5 million in Q2 2025.
• The 5-year median for Equity Average is $244.9 million (2025), against an average of $406.1 million.
• The widest annual swing landed in 2023, when Equity Average slumped 43.13%; it then grew 16.9% in 2025.
• Tracing NBP's Equity Average over 5 years: stood at $779.4 million in 2021, then slumped by 35.29% to $504.4 million in 2022, then slipped by 25.99% to $373.3 million in 2023, then tumbled by 43.87% to $209.5 million in 2024, then advanced by 16.9% to $244.9 million in 2025.
• Per Business Quant, the three latest NBP Equity Average figures stand at $244.9 million (Q4 2025), $227.8 million (Q3 2025), and $197.5 million (Q2 2025).

Peer Comparison